Suppr超能文献

膀胱癌。全剂量照射治疗患者的选择。

Bladder cancer. The selection of patients for treatment by full-dose irradiation.

作者信息

Shipley W U, Rose M A

出版信息

Cancer. 1985 May 1;55(9 Suppl):2278-84. doi: 10.1002/1097-0142(19850501)55:9+<2278::aid-cncr2820551435>3.0.co;2-#.

Abstract

Cure of muscle-invading bladder carcinoma in 20% to 39% of patients using full-dose external beam irradiation has been reported by many institutions in the last 10 years. Local failure occurs in 50% of patients so treated, however, and successful selection criteria for bladder-sparing radiotherapy are necessary. Prognostic factors which have been identified to be associated with a relatively successful outcome using full-dose irradiation include (1) the clinical stages T2 and T3, (2) the absence of ureteral obstruction on initial intravenous pyelogram, (3) a visibly "complete" transurethral resection having been achieved, and (4) complete response of the local tumor to radiation. In addition, local tumor control appears to be related to total dose administered. Analysis of the results of precystectomy radiation therapy, where papillary tumor histology and small tumor size yielded improved survival, suggests that these characteristics also may prove to be beneficial in patients selected for full-dose irradiation. The four-field box technique has become accepted as the best method to treat patients using beams from linear accelerators or betatrons. The bladder and pelvic lymph nodes should be treated to 50.4 Gy in 1.8 Gy fractions, 5 days/week. A cone-down boost to the tumor volume only then is given for a total dose of 64.8 Gy to 68.4 Gy in 7.5 weeks. The posterior rectosigmoid should receive less than 60 Gy, and the anus and femoral head and neck should be limited to 45 to 50 Gy to avoid toxicity. Innovative approaches to treatment of muscle-invading bladder cancer now are being explored and include the use of intravesical misonidazole combined with fractionated external beam irradiation, and systemic cisplatin administration in combination with radiation. Techniques which have yielded good results in superficial bladder cancer include open interstitial implantation, intraoperative single-dose electron beam irradiation, and trans-Foley radium applications. Further prospective evaluations of clinical and histologic tumor characteristics, treatment techniques and doses reviewed here will be necessary before definitive selection criteria for treatment with full-dose irradiation are established.

摘要

在过去10年中,许多机构报告称,采用全剂量外照射可治愈20%至39%的肌层浸润性膀胱癌患者。然而,接受这种治疗的患者中有50%会出现局部复发,因此,必须制定成功的膀胱保留放疗选择标准。已确定与全剂量照射相对成功的结果相关的预后因素包括:(1)临床分期为T2和T3;(2)初次静脉肾盂造影时无输尿管梗阻;(3)已实现明显的“完全”经尿道切除术;(4)局部肿瘤对放疗完全反应。此外,局部肿瘤控制似乎与给予的总剂量有关。对膀胱切除术前放疗结果的分析表明,乳头状肿瘤组织学和小肿瘤大小可提高生存率,提示这些特征对选择全剂量照射的患者可能也有益。四野盒式技术已被公认为是使用直线加速器或电子感应加速器射线治疗患者的最佳方法。膀胱和盆腔淋巴结应每周5天,每次1.8 Gy,分剂量照射至50.4 Gy。然后仅对肿瘤体积进行缩野加量照射,在7.5周内总剂量达到64.8 Gy至68.4 Gy。直肠乙状结肠后壁应接受低于60 Gy的照射,肛门、股骨头和颈部应限制在45至50 Gy,以避免毒性。目前正在探索治疗肌层浸润性膀胱癌的创新方法,包括膀胱内使用米索硝唑联合分次外照射,以及全身使用顺铂联合放疗。在浅表性膀胱癌中取得良好效果的技术包括开放组织间植入、术中单次电子束照射和经Foley导管镭敷贴。在确定全剂量照射治疗的明确选择标准之前,有必要对本文所述的临床和组织学肿瘤特征、治疗技术和剂量进行进一步的前瞻性评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验